IDH1 and cancer: D-2-HG, a well-characterized oncometabolite that is synthesized through IDH mutant enzyme, serves as a competitive inhibitor for DNA/histone demethylases, triggers genome-wide epigenetic shifts, and hence, prompts the aggressive phenotypes in cancer.